Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Preclinical Development

Targeting Radiation-Induced G2 Checkpoint Activation with the Wee-1 Inhibitor MK-1775 in Glioblastoma Cell Lines

Bhaswati Sarcar, Soumen Kahali, Antony H. Prabhu, Stuart D. Shumway, Yang Xu, Tim Demuth and Prakash Chinnaiyan
Bhaswati Sarcar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soumen Kahali
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antony H. Prabhu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart D. Shumway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yang Xu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Demuth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prakash Chinnaiyan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-11-0469 Published December 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    The influence of MK-1775 on radiation-induced G2 checkpoint activation. T98G (A), NHAs (C), and the GNS (D) cells were treated with MK-1775 (250 nmol/L, unless otherwise noted) or vehicle control 6 hours before irradiation (RT; 6 Gy) and collected at specified time points for analysis of cell-cycle phase distribution by flow cytometry. Mean ± SE of 3 independent experiments. B, mitotic ratio in T98G cells was determined using dual propidium iodide and phospho-histone H3 staining and calculated by the percentage of cells in M phase pre-/post-radiation. Results are representative of 3 independent experiments; mean ± SE.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    MK-1775 attenuates radiation-induced CDC2 phosphorylation. Tumor cell lysates from T98G cells exposed to vehicle control (C), MK-1175 (MK) alone (250 nmol/L, 16 hours), radiation alone (RT, 6 Gy), or combined with MK-1775 (250 nmol/L, 6 hours before RT) at the indicated times were resolved in SDS-PAGE and probed with specific antibodies against the indicated proteins. Results are representative of 2 independent experiments.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    The influence of MK-1775 on radiosensitivity in glioblastoma cell lines. Glioblastoma cell lines T98G (A; p53 mutant), U251 (B; p53 mutant), U87 (C; p53 wild-type), and GNS cell line G179 (D; p53 mutant) were plated, allowed to attach, and treated with either MK-1775 (100 nmol/L unless otherwise noted) or vehicle control for 6 hours pre-RT. Plates were replaced with fresh culture media after 24 hours, and surviving fractions were calculated 10 to 14 days following treatment, normalizing for the independent cytotoxicity of MK-1775. Mean ± SE of 3 independent experiments.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    MK-1775 attenuates recovery during fractionated radiation. T98G cells were plated, allowed to attach, and exposed to a single fraction of radiation (RT) or fractionated RT (2 Gy every 24 hours) at the stated doses in the presence of MK-1775 (100 nmol/L) or vehicle control. Plates were replaced with fresh culture media after 24 hours (single fraction RT) and 48 and 72 hours for plates treated with 4 and 6 Gy fractionated RT, respectively. Colony survival was determined 10 to 14 days following treatment, normalizing for the independent cytotoxicity of MK-1775. Recovery rates (RR) during fractionated RT were calculated by dividing the percentage of cell survival following fractionated RT by the percentage of cell survival following an equivalent dose of radiation delivered as a single fraction. Mean ± SE of 3 independent experiments.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    MK-1775 augments radiation-induced mitotic catastrophe and γH2AX expression. A, T98G cells growing in chamber slides were exposed to MK-1775 (250 nmol/L) or vehicle control for 6 hours, irradiated (RT, 6 Gy), and fixed at 24 hours post-irradiation for immunocytochemical analysis of mitotic catastrophe. Nuclear fragmentation (defined as the presence of 2 or more distinct lobes within a single cell) was evaluated in 100 cells per treatment per experiment. Mean ± SE (*, P = 0.03; **, P = 0.001). B, T98G cells were treated in the above described conditions, and cell lysates obtained at the indicated times were resolved in SDS-PAGE and probed with specific antibodies against the indicated proteins.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    MK-1775 enhances radiation-induced tumor growth delay and attenuates the radiation-induced G2 checkpoint arrest in vivo. A, U251 cells were injected subcutaneously in a mouse flank model. When tumors reached about 150 mm3 in size, mice were randomized into 4 groups: vehicle control, MK-1775 (60 mg/kg twice daily × 3 days), irradiation (2 Gy × 3 days; RT), or MK-1775 + irradiation. To obtain a tumor growth curve, perpendicular diameter measurements of each tumor were measured with digital calipers, and volumes were calculated using formula (L × W × W)/2. Each group contained 7 mice (*, RT vs. RT + MK-1775: P = 0.04; **, MK-1775 vs. RT + MK-1775: P = 0.001). Mean ± SE. B, U251 cells were injected subcutaneously in a mouse flank model. When tumors reached about 500 mm3 in size, mice were randomized into 3 groups: vehicle control, irradiation (6 Gy; RT), or MK-1775 (60 mg/kg twice daily, beginning 2 hours before RT) + irradiation (6 Gy). At the stated times, animals were sacrificed and tumors were removed, formalin fixed, and paraffin embedded. Immunohistochemical staining was conducted to determine the mitotic ratio by immunostaining for phospho-histone H3 expression. The entire section was then quantified using an automated system and mitotic ratio calculated, which equaled the percentage of mitotic cells in the treatment group divided by the control group.

Additional Files

  • Figures
  • Supplementary Data

    Files in this Data Supplement:

    • Supplementary Figures 1-8 - PDF file - 977K
PreviousNext
Back to top
Molecular Cancer Therapeutics: 10 (12)
December 2011
Volume 10, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Targeting Radiation-Induced G2 Checkpoint Activation with the Wee-1 Inhibitor MK-1775 in Glioblastoma Cell Lines
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Targeting Radiation-Induced G2 Checkpoint Activation with the Wee-1 Inhibitor MK-1775 in Glioblastoma Cell Lines
Bhaswati Sarcar, Soumen Kahali, Antony H. Prabhu, Stuart D. Shumway, Yang Xu, Tim Demuth and Prakash Chinnaiyan
Mol Cancer Ther December 1 2011 (10) (12) 2405-2414; DOI: 10.1158/1535-7163.MCT-11-0469

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Targeting Radiation-Induced G2 Checkpoint Activation with the Wee-1 Inhibitor MK-1775 in Glioblastoma Cell Lines
Bhaswati Sarcar, Soumen Kahali, Antony H. Prabhu, Stuart D. Shumway, Yang Xu, Tim Demuth and Prakash Chinnaiyan
Mol Cancer Ther December 1 2011 (10) (12) 2405-2414; DOI: 10.1158/1535-7163.MCT-11-0469
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • PSMA-Specific BiTE Antibody
  • BiKEs and TriKEs Enhance NK Cell Effector Function
  • Ganetespib Activity in KRAS-Mutant NSCLCs
Show more Preclinical Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement